PRESS RELEASE - June 28, 2000

Why is Molecular Engines Laboratories (MEL) strategy of developing anti-cancer drugs an attractive solution?

For more than twenty years, numerous academic institutions and a plethora of pharmaceutical companies have been working intensively in trying to grasp how normal cells become malignant. The team at Molecular Engines Laboratories is taking a novel approach towards addressing this issue.

While conventional anti-cancer approaches focus on targeting malignant cells for destruction, MEL's method of tumor eradication seeks to " reprogram " cancerous cells towards a non-malignant state.

This method, known as tumor reversion, offers a new strategy in cancer intervention. The understanding of the genetic and molecular components underlying tumor reversion will undoubtedly provide unexpected insights into developing a new generation of therapeutic agents.

Contact : Robert AMSON – Tel : 33 1 44 64 04 64 – Fax : 33 1 44 64 04 65
Email :